Advances in Molecular Biology / Moleküler Biyolojide Gelişmeler

Permanent URI for this communityhttps://hdl.handle.net/11413/164

Browse

Browsing Advances in Molecular Biology / Moleküler Biyolojide Gelişmeler by Author "Arısan, Serdar"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • Thumbnail Image
    PublicationOpen Access
    Antioxidant enzyme profile in chronic pelvic pain syndrome patients
    (İstanbul Kültür Üniversitesi Yayınları, 2007-03) Arısan, Serdar; Kiremit, Murat Can; Palavan-Ünsal, Narçin; Ergenekon, Erbil; ARISAN, ELİF DAMLA
    Chronic pelvic pain syndrome (CPPS) is a common and serious health problem affecting the quality of life in men. According to National Institute of Health classification system abacterial chronic pelvic pain has two sub category which are defined as 3a and 3b. The major difference between these two groups inflammation status. In this study we aim to investigate the antioxidant enzyme levels such as Glutathion peroxidase (Gsh-Px), superoxide dismutase (SOD), catalase (CAT) and lipid peroxidation products in CPPS patients. All enzyme levels were determined in patients and disease free control group blood samples by spectrophotometrically. In our study, the enzyme levels were not a good indicator for comparison of 3a or 3b type CPPS patients. However, Gsh-Px, SOD and lipid peroxidation products were significantly different from disease free control samples. Although high generation of H202 due to SOD activity, we did not detect any change in CAT activity in patients blood samples compare to control group.
  • Thumbnail Image
    PublicationOpen Access
    Determination of HER2/NEU gene amplification and protein overexpression ib bladder transitional cell carcinoma
    (İstanbul Kültür Üniversitesi, 2007-09) Atış, Gökhan; Arısan, Serdar; Ayhan, Dalkılınç
    HER2/neu 185 kDa is a transmembrane receptor tyrosine kinase being a part of epidermal growth factor receptor family. Especially overexpression was shown in breast cancer and treatment procedures targeting this protein are in clinical use. The aim of this study is to show the overexpression of HER2/neu in bladder TCC patients by using immunohistochemical methods. 46 TCC and 15 healthy bladder tissues as a control group were used in the study. Deparafinized tumor specimens were marked by using monoclonal antihuman HER2 protein antibody and the protein was shown by using peroxidase secondary antibody. Non-staining or membrane staining less than 10% were classified as 0, while membrane staining partly more than 10% were 1, poor complete membrane staining or moderate staining more than 10% were 2 and complete membrane strongly staining were classified as 3. Classification 2 and 3 were evaluated as over staining of HER2/neu. Overexpression of HER2/Neu protein were shown in 12/46 (24.5%) of TCC specimens. Overexpression of HER2/neu were detected in 2 (12.5%) of Grade 1, 1 (16.6%) of Grade 2 and 12 (50%) of Grade 3 patients. Overexpression of HER2/Neu protein were positive in 5 (17.8%) of 28 superficial (Ta-T1) tumor specimens and 7 (38.8%) of 18 invasive (T2-T3) tumor specimens. Overexpression of HER2/neu in Grade III tumors were statistically significant when compared with Grade I and Grade II (p=0.012). Overexpression of HER2/neu detected in bladder TCC will be used in clinical setting as a treatment option targeting this protein as in the breast cancer in the future.
  • Thumbnail Image
    PublicationOpen Access
    Determination of IL-10 levels in chronic pelvic pain syndrome patients
    (İstanbul Kültür Üniversitesi, 2008) Arısan, Serdar; Kiremit, Murat Can; Ergenekon, Erbil; Çaşkurlu, Turhan
    Chronic pelvic pain syndrome (CPPS) is very common pathology that is characterized by pain in the perineum, pelvis, supra pubic area, or the external genitalia, with variable degrees of voiding or ejaculatory disturbance. The etiology of disorder is controversial with groups postulating infections, autoimmune, inflammatory and neuromascular mechanism. CPPS is the most commonurologic diagnosisin men younger than 50 years and the third most common urologic diagnosis in men older than 50 years after benign prostate hyperplasia and prostate cancer. Although high incidence rate, the etiology and pathophysiology of the disease are still poor.